Rheumatoid Arthritis (RA) is an autoimmune disease characterized by inflammation and eventual destruction of the synovial joints. The role of platelets in the pathophysiology of arthritis has only recently been established. Because antibodies to CD44 can deplete platelets, we hypothesized that these antibodies might be effective in arthritis through a platelet-depletion mechanism. We examined the K/BxN passive transfer mouse model of arthritis and found that most antibodies against CD44 were capable of depleting platelets. However, anti-CD44 treatment is effective when administered during developing arthritis, while anti-platelet treatment was not. While CD44 antibodies may be therapeutic through platelet-dependant and independent mechanisms, the ability of CD44 antibodies to decrease platelet counts does not seem to be the critical factor in resolving arthritis in the K/BxN model.

Thesis (M.D.)--University of Adelaide, Dept. of Medicine, 1988.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2007. / Härtill 6 uppsatser.

Diss. (sammanfattning) Uppsala : Uppsala universitet, 2005. / Härtill 5 uppsatser.

Diss. (sammanfattning) Uppsala : Univ., 2005. / Härtill 4 uppsatser.

Thesis (Ph.D.)--University of Adelaide, Dept. of Medicine, 1997. / Copy of author's previously published article. Bibliography: leaves 189-219.

Thesis (Ph.D.) - University of Queensland, 2005. / Includes bibliography.

Thesis (M.S.)--University of Wisconsin--Madison, 1982. / eContent provider-neutral record in process. Description based on print version record. Typescript. Includes bibliographical references (leaves 105-114).

Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease that can lead to important functional impairment. Although improvements in treatment have been made, still there are a high proportion of patients in whom response to treatment is not complete. Fibromyalgia (FM) is a condition characterized by bodily pain that often coexists with RA. Cross-sectional studies have shown that patients with RA and FM symptoms, or fibromyalgic RA (FRA), have higher disease activity scores than patients with RA and no FRA. Concern has been raised regarding the validity of RA disease activity scores in patients with coexistent RA and FM. In this prospective study, we hypothesized that patients with FRA have an impaired response to treatment measured by traditionally used scores. The present analysis used a study sample obtained from the ESPOIR French cohort. This is a longitudinal prospective cohort of adults with early RA. Patients with RA were classified in two groups according to the presence of FRA. RA disease activity scores (DAS28, SDAI, CDAI and HAQ) were compared as a measure of response to treatment at 6, 12 and 18 months. Results showed that after adjusting for confounders, patients with FRA (120) had higher activity scores than patients with RA and no fibromyalgic characteristics (548). DAS28 and other disease activity scores started out higher in subjects with FRA and while they improved to a similar extent as in the isolated RA group, they remained consistently higher among FRA patients. Achievement of low disease activity and of remission according to established activity score cut-points was significantly less likely in subjects with FRA. In conclusion, patients with FRA and RA had a similar response to treatment according the decrease in indexes of disease activity but more frequently missed the target of remission or low disease activity. These findings may have implications in RA treatment in patients with FRA, as therapy is escalated not in relation to change in scores but to achieving remission.

No description available.